<div id="Tab1" class="Table">
<div class="Caption" lang="en"><div class="CaptionContent">
<span class="CaptionNumber">Table 1</span> <p class="SimplePara">Patient demographics and baseline clinical characteristics</p> </div></div>
<div class="u-scroll-horizontal"><table>
<colgroup>
<col class="tcol1 align-left">
<col class="tcol2 align-left">
<col class="tcol3 align-left">
<col class="tcol4 align-left">
</colgroup>
<thead><tr>
<th> <p class="SimplePara">Characteristic</p> </th>
<th> <p class="SimplePara">Secukinumab 150 mg (<em class="EmphasisTypeItalic ">N</em> = 116)</p> </th>
<th> <p class="SimplePara">Secukinumab 150 mg no load (<em class="EmphasisTypeItalic ">N</em> = 117)</p> </th>
<th> <p class="SimplePara">Placebo (<em class="EmphasisTypeItalic ">N</em> = 117)</p> </th>
</tr></thead>
<tbody>
<tr>
<td> <p class="SimplePara">Age (years), mean ± SD</p> </td>
<td> <p class="SimplePara">44.5 ± 11.62</p> </td>
<td> <p class="SimplePara">41.2 ± 11.07</p> </td>
<td> <p class="SimplePara">43.4 ± 12.46</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Male, <em class="EmphasisTypeItalic ">n</em> (%)</p> </td>
<td> <p class="SimplePara">81 (69.8)</p> </td>
<td> <p class="SimplePara">83 (70.9)</p> </td>
<td> <p class="SimplePara">76 (65.0)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Caucasian, <em class="EmphasisTypeItalic ">n</em> (%)</p> </td>
<td> <p class="SimplePara">113 (97.4)</p> </td>
<td> <p class="SimplePara">117 (100)</p> </td>
<td> <p class="SimplePara">114 (97.4)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Weight (kg), mean ± SD</p> </td>
<td> <p class="SimplePara">83.4 ± 20.35</p> </td>
<td> <p class="SimplePara">80.3 ± 18.23</p> </td>
<td> <p class="SimplePara">80.6 ± 17.10</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Time since AS diagnosis (years), mean ± SD</p> </td>
<td> <p class="SimplePara">8.4 ± 10.84</p> </td>
<td> <p class="SimplePara">6.5 ± 7.55</p> </td>
<td> <p class="SimplePara">7.1 ± 9.23</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">HLA-B27 positive at baseline, <em class="EmphasisTypeItalic ">n</em> (%)</p> </td>
<td> <p class="SimplePara">100 (86.2)</p> </td>
<td> <p class="SimplePara">99 (84.6)</p> </td>
<td> <p class="SimplePara">93 (79.5)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">TNFi-naïve, <em class="EmphasisTypeItalic ">n</em> (%)</p> </td>
<td> <p class="SimplePara">85 (73.3)</p> </td>
<td> <p class="SimplePara">85 (72.6)</p> </td>
<td> <p class="SimplePara">83 (70.9)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Total BASDAI score, mean ± SD</p> </td>
<td> <p class="SimplePara">7.0 ± 1.23</p> </td>
<td> <p class="SimplePara">6.95 ± 1.31</p> </td>
<td> <p class="SimplePara">7.1 ± 1.27</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">hsCRP (mg/l), median (min–max)</p> </td>
<td> <p class="SimplePara">6.25</p> <p class="SimplePara">(0.4–123.0)</p> </td>
<td> <p class="SimplePara">6.20</p> <p class="SimplePara">(0.3–120.9)</p> </td>
<td> <p class="SimplePara">5.40</p> <p class="SimplePara">(0.3–129.3)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Total back pain score (0–100 mm scale), mean ± SD</p> </td>
<td> <p class="SimplePara">74.9 ± 13.07</p> </td>
<td> <p class="SimplePara">74.2 ± 14.18</p> </td>
<td> <p class="SimplePara">75.0 ± 13.80</p> </td>
</tr>
<tr><td colspan="4"> <p class="SimplePara">Previous systemic treatment, <em class="EmphasisTypeItalic ">n</em> (%)</p> </td></tr>
<tr>
<td> <p class="SimplePara"> Methotrexate use at randomization</p> </td>
<td> <p class="SimplePara">11 (9.5)</p> </td>
<td> <p class="SimplePara">11 (9.4)</p> </td>
<td> <p class="SimplePara">10 (8.5)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Sulfasalazine use at randomization</p> </td>
<td> <p class="SimplePara">16 (13.8)</p> </td>
<td> <p class="SimplePara">16 (13.7)</p> </td>
<td> <p class="SimplePara">27 (23.1)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Corticosteroid use at randomization</p> </td>
<td> <p class="SimplePara">11 (9.5)</p> </td>
<td> <p class="SimplePara">10 (8.5)</p> </td>
<td> <p class="SimplePara">13 (11.1)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara">Cumulative NSAID score, mean ± SD</p> </td>
<td> <p class="SimplePara">64.0 (46.10)</p> </td>
<td> <p class="SimplePara">68.3 (46.20)</p> </td>
<td> <p class="SimplePara">60.4 (51.25)</p> </td>
</tr>
<tr><td colspan="4"> <p class="SimplePara">Medical history,<em class="EmphasisTypeItalic "> n</em> (%)</p> </td></tr>
<tr>
<td> <p class="SimplePara"> Uveitis</p> </td>
<td> <p class="SimplePara">23 (19.8)</p> </td>
<td> <p class="SimplePara">21 (17.9)</p> </td>
<td> <p class="SimplePara">27 (23.1)</p> </td>
</tr>
<tr>
<td> <p class="SimplePara"> Inflammatory bowel disease</p> </td>
<td> <p class="SimplePara">2 (1.7)</p> </td>
<td> <p class="SimplePara">4 (3.4)</p> </td>
<td> <p class="SimplePara">0</p> </td>
</tr>
</tbody>
</table></div>
<div class="TableFooter"> <p class="SimplePara"><em class="EmphasisTypeItalic ">AS</em> ankylosing spondylitis, <em class="EmphasisTypeItalic ">BASDAI</em> Bath Ankylosing Spondylitis Disease Activity Index, <em class="EmphasisTypeItalic ">hsCRP</em> high-sensitivity C-reactive protein, <em class="EmphasisTypeItalic ">HLA</em> human leukocyte antigen, <em class="EmphasisTypeItalic ">N</em> number of patients randomized, <em class="EmphasisTypeItalic ">n</em> number of responders, <em class="EmphasisTypeItalic ">NSAID</em> non-steroidal anti-inflammatory drugs, <em class="EmphasisTypeItalic ">s.c.</em> subcutaneous, <em class="EmphasisTypeItalic ">SD</em> standard deviation, <em class="EmphasisTypeItalic ">TNFi</em> tumor necrosis factor-alpha inhibitors</p> </div>
</div>